These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24446277)

  • 21. The monitoring medicines project: a multinational pharmacovigilance and public health project.
    Pal SN; Olsson S; Brown EG
    Drug Saf; 2015 Apr; 38(4):319-28. PubMed ID: 25829215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving the Safety of Medicines in the European Union: From Signals to Action.
    Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
    Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient Reporting in the EU: Analysis of EudraVigilance Data.
    Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
    Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychiatric adverse drug reactions in the paediatric population.
    Ekhart C; Vries T; Hunsel FV
    Arch Dis Child; 2020 Aug; 105(8):749-755. PubMed ID: 32060030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medication Errors Associated With Adverse Drug Reactions in Iran (2015-2017): A P-Method Approach.
    Karimian Z; Kheirandish M; Javidnikou N; Asghari G; Ahmadizar F; Dinarvand R
    Int J Health Policy Manag; 2018 Dec; 7(12):1090-1096. PubMed ID: 30709084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacovigilance in pediatrics.
    Bouquet É; Star K; Jonville-Béra AP; Durrieu G
    Therapie; 2018 Apr; 73(2):171-180. PubMed ID: 29598957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance.
    Newbould V; Le Meur S; Goedecke T; Kurz X
    Drug Saf; 2017 Dec; 40(12):1241-1248. PubMed ID: 28698988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Children and ADRs (Adverse Drug Reactions).
    Napoleone E
    Ital J Pediatr; 2010 Jan; 36():4. PubMed ID: 20180963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medication errors through a national pharmacovigilance database approach: a study for Malta.
    Tanti A; Camilleri M; Bonanno PV; Borg JJ
    Int J Risk Saf Med; 2013 Jan; 25(1):17-27. PubMed ID: 23442294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication.
    Varallo FR; Forgerini M; Herdeiro MT; de Carvalho Mastroianni P
    Clin Ther; 2019 Mar; 41(3):598-603. PubMed ID: 30792075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central nervous system-active drug abused and overdose in children: a worldwide exploratory study using the WHO pharmacovigilance database.
    Carnovale C; Mahzar F; Scibelli S; Gentili M; Arzenton E; Moretti U; Leoni O; Pozzi M; Peeters GGAM; Clementi E; Medaglia M; Radice S
    Eur J Pediatr; 2019 Feb; 178(2):161-172. PubMed ID: 30374752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Definitions related to pharmacovigilance and drug safety].
    Möller H; Aly AF
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(10):709-11. PubMed ID: 23217722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacovigilance in developing countries (part II): a path forward.
    Elshafie S; Roberti AM; Zaghloul I
    Int J Clin Pharm; 2018 Aug; 40(4):764-768. PubMed ID: 29322474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacovigilance in developing countries (part I): importance and challenges.
    Elshafie S; Zaghloul I; Roberti AM
    Int J Clin Pharm; 2018 Aug; 40(4):758-763. PubMed ID: 29248988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety signal detection: the relevance of literature review.
    Pontes H; Clément M; Rollason V
    Drug Saf; 2014 Jul; 37(7):471-9. PubMed ID: 24895178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017.
    Farcaş A; Măhălean A; Bulik NB; Leucuta D; Mogoșan C
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1045-1051. PubMed ID: 30269618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.